Is CD44 a Marker for Cancer Stem Cells?

  • Thalia Blacking
Part of the Stem Cells and Cancer Stem Cells book series (STEM, volume 9)


CD44 is a cell surface transmembrane glycoprotein involved in cell adhesion and migration, and also the regulation of numerous intracellular signalling events. As well as the ubiquitously expressed standard form, alternative splicing and post-translational modification give rise to numerous variant isoforms. Altered expression of CD44 occurs in cancer, particularly in association with invasion and metastasis. More recently the molecule has received considerable attention as a potential marker of cancer stem cells (CSC). The CD44+ fraction of numerous tumours has been reported to demonstrate enhanced tumourigenic potential and the ability to recapitulate the parental tumour. Blockade of CD44 may therefore represent a means of eliminating the putative tumour-propagating CSC fraction of some tumours.

However, CD44 is not a universal marker of CSC. More fundamentally, some evidence suggests that the CD44+ CSC phenotype could be unstable, or even acquired by cells within the CD44 fraction, questioning the concept of CD44+ cancer cells existing at the apex of a unidirectional developmental hierarchy. Moreover, any notion of targetting CD44 will be complicated by its widespread expression on normal cells. Thus, although many features of CD44 make it an attractive candidate as a CSC marker, there is need for a greater understanding of the significance of expression, and in particular the expression of variant isoforms, in the context of putative cellular hierarchies in cancer.


Cancer Stem Cell Clonal Evolution Normal Stem Cell Cancer Stem Cell Marker Cancer Stem Cell Population 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abraham BK, Fritz P, Mcclellan M, Hauptvogel P, Athelogou M, Brauch H (2005) Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11:1154–1159PubMedGoogle Scholar
  2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988PubMedCrossRefGoogle Scholar
  3. Alho AM, Underhill CB (1989) The hyaluronate receptor is preferentially expressed on proliferating epithelial cells. J Cell Biol 108:1557–1565PubMedCrossRefGoogle Scholar
  4. Balic M, Lin H, Young L, Hawes D, Giuliano A, Mcnamara G, Datar RH, Cote RJ (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12:5615–5621PubMedCrossRefGoogle Scholar
  5. Barabe F, Kennedy JA, Hope KJ, Dick JE (2007) Modeling the initiation and progression of human acute leukemia in mice. Science 316:600–604PubMedCrossRefGoogle Scholar
  6. Blacking TM, Waterfall M, Argyle DJ (2011) CD44 is associated with proliferation, rather than a specific cancer stem cell population, in cultured canine cancer cells. Vet Immunol Immunopathol 141:46–57PubMedCrossRefGoogle Scholar
  7. Bourguignon LY, Xia W, Wong G (2009) Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J Biol Chem 284:2657–2671PubMedCrossRefGoogle Scholar
  8. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B, Weinberg RA (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 108:7950–7955PubMedCrossRefGoogle Scholar
  9. Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R (2001) CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 153:1277–1286PubMedCrossRefGoogle Scholar
  10. Draffin JE, Mcfarlane S, Hill A, Johnston PG, Waugh DJ (2004) CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 64:5702–5711PubMedCrossRefGoogle Scholar
  11. Driessens MH, Stroeken PJ, Rodriguez Erena NF, Van Der Valk MA, Van Rijthoven EA, Roos E (1995) Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity. J Cell Biol 131:1849–1855PubMedCrossRefGoogle Scholar
  12. Filippov V, Filippova M, Duerksen-Hughes PJ (2007) The early response to DNA damage can lead to activation of alternative splicing activity resulting in CD44 splice pattern changes. Cancer Res 67:7621–7630PubMedCrossRefGoogle Scholar
  13. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A, Simmons DL (1994) Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 54:4539–4546PubMedGoogle Scholar
  14. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, Mcallister SS, Jacks T, Weinberg RA (2008) Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134:62–73PubMedCrossRefGoogle Scholar
  15. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13–24PubMedCrossRefGoogle Scholar
  16. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146:633–644PubMedCrossRefGoogle Scholar
  17. Haegel H, Dierich A, Ceredig R (1994) CD44 in differentiated embryonic stem cells: surface expression and transcripts encoding multiple variants. Dev Immunol 3:239–246PubMedCrossRefGoogle Scholar
  18. Harper LJ, Costea DE, Gammon L, Fazil B, Biddle A, Mackenzie IC (2010) Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer 10:166PubMedCrossRefGoogle Scholar
  19. Hart IR, Birch M, Marshall JF (1991) Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev 10:115–128PubMedCrossRefGoogle Scholar
  20. Hebbard L, Steffen A, Zawadzki V, Fieber C, Howells N, Moll J, Ponta H, Hofmann M, Sleeman J (2000) CD44 expression and regulation during mammary gland development and function. J Cell Sci 113(Pt 14):2619–2630PubMedGoogle Scholar
  21. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323PubMedCrossRefGoogle Scholar
  22. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12:1167–1174PubMedCrossRefGoogle Scholar
  23. Jung T, Castellana D, Klingbeil P, Cuesta Hernandez I, Vitacolonna M, Orlicky DJ, Roffler SR, Brodt P, Zoller M (2009) CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 11:1093–1105PubMedGoogle Scholar
  24. Khaldoyanidi S, Denzel A, Zoller M (1996) Requirement for CD44 in proliferation and homing of hematopoietic precursor cells. J Leukoc Biol 60:579–592PubMedGoogle Scholar
  25. Kondo K, Miyoshi T, Hino N, Shimizu E, Masuda N, Takada M, Uyama T, Monden Y (1998) High frequency expressions of CD44 standard and variant forms in non-small cell lung cancers, but not in small cell lung cancers. J Surg Oncol 69:128–136PubMedCrossRefGoogle Scholar
  26. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chung IY, Kim IA, Kim EJ, Choi Y, Ryu HS, Park SY (2011) An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 104:1730–1738PubMedCrossRefGoogle Scholar
  27. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037PubMedCrossRefGoogle Scholar
  28. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715PubMedCrossRefGoogle Scholar
  29. Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35:211–231PubMedCrossRefGoogle Scholar
  30. Misra S, Ghatak S, Toole BP (2005) Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 280:20310–20315PubMedCrossRefGoogle Scholar
  31. Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T, Kincade PW (1990) Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. J Exp Med 171:477–488PubMedCrossRefGoogle Scholar
  32. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28PubMedCrossRefGoogle Scholar
  33. Oertl A, Castein J, Engl T, Beecken WD, Jonas D, Melamed R, Blaheta RA (2005) Endothelial adhesion of synchronized gastric tumor cells changes during cell cycle transit and correlates with the expression level of CD44 splice variants. World J Gastroenterol 11:6243–6248PubMedGoogle Scholar
  34. Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringner M, Vallon-Christersson J, Jonsson G, Holm K, Lovgren K, Ferno M, Grabau D, Borg A, Hegardt C (2011) CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11:418PubMedCrossRefGoogle Scholar
  35. Protin U, Schweighoffer T, Jochum W, Hilberg F (1999) CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets. J Immunol 163:4917–4923PubMedGoogle Scholar
  36. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598PubMedCrossRefGoogle Scholar
  37. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, Herrlich P, Matzku S, Zoller M (1993) Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177:443–455PubMedCrossRefGoogle Scholar
  38. Sherman L, Wainwright D, Ponta H, Herrlich P (1998) A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev 12:1058–1071PubMedCrossRefGoogle Scholar
  39. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259–273PubMedCrossRefGoogle Scholar
  40. Stamenkovic I, Aruffo A, Amiot M, Seed B (1991) The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 10:343–348PubMedGoogle Scholar
  41. Sugino T, Gorham H, Yoshida K, Bolodeoku J, Nargund V, Cranston D, Goodison S, Tarin D (1996) Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 149:873–882PubMedGoogle Scholar
  42. Sy MS, Guo YJ, Stamenkovic I (1991) Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 174:859–866PubMedCrossRefGoogle Scholar
  43. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454PubMedCrossRefGoogle Scholar
  44. Thomas L, Byers HR, Vink J, Stamenkovic I (1992) CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol 118:971–977PubMedCrossRefGoogle Scholar
  45. Vermeulen L, Todaro M, De Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP (2008) Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 105:13427–13432PubMedCrossRefGoogle Scholar
  46. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW (2002) Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 62:2281–2286PubMedGoogle Scholar
  47. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST (1999) Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154:515–523PubMedCrossRefGoogle Scholar
  48. Yu Q, Toole BP, Stamenkovic I (1997) Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 186:1985–1996PubMedCrossRefGoogle Scholar
  49. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST (2008) Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 68:3655–3661PubMedCrossRefGoogle Scholar
  50. Zoller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11:254–267PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Comparative Oncology and Stem Cell Research Group, The Royal (Dick) School of Veterinary Studies and Roslin InstituteThe University of EdinburghMidlothianUK

Personalised recommendations